During this episode, Lynora Saxinger, MD, FRCPC, CTropMed, updates listeners on the latest Emergency Use Authorizations and guideline recommendations for optimal clinical management of COVID-19. Gain practical insights on patient identification, risk stratification, and treatment.Key points include:Treatment of COVID-19 can be broken into antiviral and immune-modulating therapiesEach agent should be used at the correct disease stage to maximize benefitAntiviral medications and mAbs show the greatest promise early during COVID-19, before the host immune response is mountedPassive immunization with mAbs can prevent infection and severe disease—and mortality—if given early to hospitalized personsOperational challenges to using these medications exist, but given the epidemic of unvaccinated persons, these treatments become increasingly relevant to reduce burden on healthcare systemsPresenter:Lynora Saxinger, MD, FRCPC, CTropMedCochair, Scientific Advisory Group Alberta COVID-19 Emergency Coordination Centre Associate ProfessorDivision of Infectious DiseasesDepartment of Medicine University of AlbertaEdmonton, Alberta, CanadaContent based on an online CME program supported by an educational grant from Gilead Sciences, Inc.Follow along with the slides at:https://bit.ly/3BxQKtD Link to full program:https://bit.ly/3BwzdlC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related